Industry
Biotechnology
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
Loading...
Open
16.66
Mkt cap
1.1B
Volume
528K
High
16.95
P/E Ratio
-11.16
52-wk high
17.26
Low
16.44
Div yield
N/A
52-wk low
6.93
Portfolio Pulse from
November 05, 2024 | 12:30 pm
Portfolio Pulse from Benzinga Newsdesk
November 01, 2024 | 11:32 am
Portfolio Pulse from Benzinga Newsdesk
November 01, 2024 | 11:25 am
Portfolio Pulse from Benzinga Newsdesk
October 31, 2024 | 8:09 pm
Portfolio Pulse from Benzinga Newsdesk
October 28, 2024 | 1:52 pm
Portfolio Pulse from Nabaparna Bhattacharya
October 25, 2024 | 10:07 am
Portfolio Pulse from Benzinga Insights
October 22, 2024 | 2:01 pm
Portfolio Pulse from Benzinga Newsdesk
October 22, 2024 | 11:09 am
Portfolio Pulse from Benzinga Newsdesk
October 21, 2024 | 10:04 am
Portfolio Pulse from Benzinga Newsdesk
September 25, 2024 | 10:52 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.